Janux Therapeutics Inc

General ticker "JANX" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $3.1B

Janux Therapeutics Inc follows the US Stock Market performance with the rate: 43.0%.

Estimated limits based on current volatility of 4.2%: low 54.94$, high 57.94$

Factors to consider:

  • Current price 337.2% above estimated high
  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [6.00$, 12.98$]
  • 2024-12-30 to 2025-12-30 estimated range: [5.95$, 12.74$]

Financial Metrics affecting the JANX estimates:

  • Negative: Non-GAAP EPS, $ of -1.34 <= 0.10
  • Negative: Operating profit margin, % of -90.03 <= 1.03
  • Positive: -0.96 < Investing cash flow per share, $ of -0.94
  • Negative: negative Net income
  • Negative: Operating cash flow per share per price, % of -10.54 <= 2.35
  • Positive: Industry inventory ratio change (median), % of 0 <= 0

Similar symbols

Short-term JANX quotes

Long-term JANX plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $3.64MM $8.61MM $8.08MM
Operating Expenses $36.57MM $75.70MM $81.06MM
Operating Income $-32.93MM $-67.09MM $-72.98MM
Non-Operating Income $0.26MM $4.03MM $14.69MM
R&D Expense $26.24MM $53.44MM $54.92MM
Income(Loss) $-32.67MM $-63.06MM $-58.29MM
Profit(Loss) $-32.67MM $-63.06MM $-58.29MM
Stockholders Equity $366.33MM $320.74MM $344.35MM
Inventory $0.20MM $0.70MM $0.00MM
Assets $379.82MM $364.01MM $380.41MM
Operating Cash Flow $-16.98MM $-42.92MM $-50.58MM
Capital expenditure $1.48MM $6.45MM $1.85MM
Investing Cash Flow $-340.96MM $58.27MM $-41.19MM
Financing Cash Flow $386.52MM $0.50MM $59.55MM
Earnings Per Share* $-0.79 $-1.31 $-1.32

* EPS are Split Adjusted, recent splits may be reflected with a delay.